The FDA decision to approve the supplemental biologics license application for dupilumab (Dupixent) follows recent pivotal clinical trial data assessing 106 patients.
Our top 5 headlines include a target date for a cholesterol-lowering drug, long-term dermatology data, and an expanded dosing label for geographic atrophy.